Ken Griffin's position in Immunovant is currently worth $22 Million. That's 0.02% of their equity portfolio (739th largest holding). The first Immunovant trade was made in Q1 2020. Since then Ken Griffin bought shares six more times and sold shares on eight occasions. The stake costed the investor $15.7 Million, netting the investor a gain of 41% so far.